Is triglycerides a better monitoring choice than LDL-C on cagrilintide?

The specifics, since they change the answer: triglycerides · LDL-C · cagrilintide.

The comparison I want does not seem to exist anywhere in a form I can evaluate.

I have read the arguments for each and they do not engage with each other.

So which one, and on what grounds?

Answer first: decide what you would do differently for each possible result before you order the panel. Anything that fails that test is a number you will worry about and not act on.

A twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.

Relative to absolute, worked

The last two rows describe the same finding. Only one of them is used in headlines.

Haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.

Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.

The caveat is that a panel is not a diagnosis and interpreting one is a clinician's job, particularly when several values move together.

Keep the full report, not the number. You will need the units and the interval later.

The relevant statistical point is that a ninety-five per cent reference interval means one analyte in twenty will read out of range in a healthy person by construction.

Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.

Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.

Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.

Ordering tests you will not act on generates anxiety and incidental findings, both of which have costs.

One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.

Standardise the conditions — same time of day, same fasting state, same laboratory — or you are measuring the conditions rather than yourself.

Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.

On the detail: same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.

Same laboratory, same time, same fasting state, or the comparison is not a comparison.

edited 23 Dec 2024 by h_villanueva — tightened the wording; no substantive change

The honest position is that most people order too many analytes and too few time points, when the reverse would be more informative.

A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.

Decide the action for each result before you order the test.

The short version: a small, well-chosen panel with a baseline beats a large one without.

Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.

Baseline first, then a repeat under identical conditions. Everything else is secondary.